Form 8-k

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2010

 

 

MAP PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-33719   20-0507047

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

2400 Bayshore Parkway, Suite 200, Mountain

View, CA

  94043
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 386-3100

 

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events

In a press release issued on May 11, 2010, MAP Pharmaceuticals, Inc. (the “Company”) provided an update on the Phase 3 development program for its LEVADEX™ product candidate for the potential treatment of acute migraine. The Company announced that it currently expects to file a New Drug Application (“NDA”) for LEVADEX with the United States Food and Drug Administration during the first half of 2011. The Company also announced that it will conduct a QT clinical trial, to evaluate whether LEVADEX has an effect on QT interval as measured by electrocardiogram, in support of the NDA. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit
No.

  

Description

99.1    Press Release of MAP Pharmaceuticals, Inc., dated May 11, 2010


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 11, 2010

 

MAP PHARMACEUTICALS, INC.

By:  

/S/    CHARLENE A. FRIEDMAN        

Name:   Charlene A. Friedman
Title:   Vice President, General Counsel and Secretary


INDEX TO EXHIBITS FILED WITH

THE CURRENT REPORT ON FORM 8-K DATED MAY 11, 2010

 

Exhibit

  

Description

99.1    Press Release of MAP Pharmaceuticals, Inc., dated May 11, 2010